Sources / A regulatory filing

Recursion Pharmaceuticals, Form 10-K for 2025 (SEC), note on the Tempus agreement

1 record was read from this source, dated Nov 2023.

Its permanent copy is being made in the Wayback Machine.

Last checked 14 Oct 2026

What was read from it

Records read from this source
Record	Kind	As stated	Dated
Access to Tempus's de-identified multimodal oncology patient records for drug discovery, five-year licence to Recursion	Price observation	annual license fees ranging between $22.0 million and $42.0 million per year of a…	Nov 2023

Figures it feeds